Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CC17 group B Streptococcus exploits integrins for neonatal meningitis development
Romain Deshayes de Cambronne, Agnès Fouet, Amandine Picart, Anne-Sophie Bourrel, Cyril Anjou, Guillaume Bouvier, Cristina Candeias, Abdelouhab Bouaboud, Lionel Costa, Anne-Cécile Boulay, Martine Cohen-Salmon, Isabelle Plu, Caroline Rambaud, Eva Faurobert, Corinne Albigès-Rizo, Asmaa Tazi, Claire Poyart, Julie Guignot
Romain Deshayes de Cambronne, Agnès Fouet, Amandine Picart, Anne-Sophie Bourrel, Cyril Anjou, Guillaume Bouvier, Cristina Candeias, Abdelouhab Bouaboud, Lionel Costa, Anne-Cécile Boulay, Martine Cohen-Salmon, Isabelle Plu, Caroline Rambaud, Eva Faurobert, Corinne Albigès-Rizo, Asmaa Tazi, Claire Poyart, Julie Guignot
View: Text | PDF
Research Article Infectious disease Microbiology

CC17 group B Streptococcus exploits integrins for neonatal meningitis development

  • Text
  • PDF
Abstract

Group B Streptococcus (GBS) is the major cause of human neonatal infections. A single clone, designated CC17-GBS, accounts for more than 80% of meningitis cases, the most severe form of the infection. However, the events allowing blood-borne GBS to penetrate the brain remain largely elusive. In this study, we identified the host transmembrane receptors α5β1 and αvβ3 integrins as the ligands of Srr2, a major CC17-GBS–specific adhesin. Two motifs located in the binding region of Srr2 were responsible for the interaction between CC17-GBS and these integrins. We demonstrated in a blood-brain-barrier cellular model that both integrins contributed to the adhesion and internalization of CC17-GBS. Strikingly, both integrins were overexpressed during the postnatal period in the brain vessels of the blood-brain barrier and blood-cerebrospinal fluid barrier and contributed to juvenile susceptibility to CC17 meningitis. Finally, blocking these integrins decreased the ability of CC17-GBS to cross into the CNS of juvenile mice in an in vivo model of meningitis. Our study demonstrated that CC17-GBS exploits integrins in order to cross the brain vessels, leading to meningitis. Importantly, it provides host molecular insights into neonate’s susceptibility to CC17-GBS meningitis, thereby opening new perspectives for therapeutic and prevention strategies of GBS-elicited meningitis.

Authors

Romain Deshayes de Cambronne, Agnès Fouet, Amandine Picart, Anne-Sophie Bourrel, Cyril Anjou, Guillaume Bouvier, Cristina Candeias, Abdelouhab Bouaboud, Lionel Costa, Anne-Cécile Boulay, Martine Cohen-Salmon, Isabelle Plu, Caroline Rambaud, Eva Faurobert, Corinne Albigès-Rizo, Asmaa Tazi, Claire Poyart, Julie Guignot

×

Figure 2

Identification of BRSrr2 residues involved in the direct interaction with αvβ3 and α5β1 integrins.

Options: View larger image (or click on image) Download as PowerPoint
Identification of BRSrr2 residues involved in the direct interaction wit...
(A and B) Interaction of BRSrr2 or its mutated forms with integrins αvβ3 (A) or α5β1 (B) assessed by ELISA. Mutated forms of BRSrr2 proteins are shown in Supplemental Figure 1, B and C. (C and D) Interaction of BRSrr2 with integrins αvβ3 (C) or α5β1 (D) in the presence of increasing concentration of mimetic peptides assessed by ELISA. Results are expressed as percentage of untreated condition. (E) Graphic representation of predicted contacts between BRSrr2 and α5β1 integrin identified by RaptorX (Supplemental Figure 4). RaptorX mapped on the α5 (gray) and β1 (green) integrin subunits predicted 2 contact zones located in the N-terminal (blue) and C-terminal (gold) domains of BRSrr2. Only the most reliable contacts (contact probability > 0.7) are depicted as yellow lines in the scheme. (F) Schematic representation of BRSrr2 or its truncated forms. Numbers in black indicate the position of amino acid residues in Srr2, and letters in white indicate the predicted motifs of interaction with the integrin α5β1. (G) ELISA assays with integrin α5β1 were performed using equimolar amounts of coated BRSrr2 or of its truncated forms. (H) Interaction of BRSrr2 or its mutated forms with the integrin α5β1 was assessed by ELISA. Mutated forms of BRSrr2 proteins are shown in Supplemental Figure 1, D and E. ELISA results were normalized to the negative control (BSA). Statistical analysis: data shown are mean ± SEM of at least 3 independent experiments. Two-way ANOVA with Bonferroni’s multiple-comparison posttest performed. NS, nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts